MedTrace Logo

Cancer Treatment Related Cardiovascular Toxicity: Comprehensive Myocardial and Vascular Phenotyping

NCT06048458 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 75

Last updated 2023-09-21

No results posted yet for this study

Summary

Observational prospective cohort study designed to assess the mechanisms of fluoropyrimidine induced cardiovascular toxicity.

Conditions

Interventions

DIAGNOSTIC_TEST

Cardiovascular magnetic resonance with stress perfusion

Cardiac MRI scan to assess changes in left ventricular function, parametric mapping, strain and myocardial blood flow. In cohort 1 this will be performed pre, during and on completion of treatment. In cohort 2 this will be performed during the acute presentation and on completion of treatment.

DIAGNOSTIC_TEST

CT coronary angiography

CT coronary angiogram at baseline only in both cohorts to assess for coronary artery disease

DIAGNOSTIC_TEST

Retinal OCT angiography

Retinal OCTa to assess changes in retinal vasculature. In cohort 1 this will be performed pre, during and on completion of treatment. In cohort 2 this will be performed during the acute presentation and on completion of treatment.

DIAGNOSTIC_TEST

Sublingual microscopy (GlycoCheck)

To determine changes in sublingual microvascular health. In cohort 1 this will be performed pre, during and on completion of treatment. In cohort 2 this will be performed during the acute presentation and on completion of treatment.

DIAGNOSTIC_TEST

Serum cardiac biomarkers (High sensitivity troponin, NT pro BNP)

Performed to assess for myocardial injury. In cohort 1 this will be performed pre, during and on completion of treatment. In cohort 2 this will be performed during the acute presentation and on completion of treatment.

Sponsors & Collaborators

  • University College, London

    lead OTHER

Principal Investigators

  • Charlotte Manisty, PhD · UCL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-05-18
Primary Completion
2023-12-31
Completion
2024-02-29

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06048458 on ClinicalTrials.gov